Turn Therapeutics (NASDAQ:TTRX) Upgraded to “Strong-Buy” at D Boral Capital

Turn Therapeutics (NASDAQ:TTRX) was upgraded by stock analysts at D Boral Capital to a “strong-buy” rating in a report released on Monday, Marketbeat Ratings reports.

Separately, D. Boral Capital assumed coverage on shares of Turn Therapeutics in a research note on Monday. They set a “buy” rating and a $8.00 target price for the company. One analyst has rated the stock with a Strong Buy rating and one has issued a Buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Strong Buy” and an average target price of $8.00.

Turn Therapeutics Stock Performance

TTRX opened at $3.71 on Monday. Turn Therapeutics has a one year low of $2.57 and a one year high of $26.50. The firm has a 50 day simple moving average of $3.57.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Thursday, November 13th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Insider Activity

In other Turn Therapeutics news, insider Abraham Chesed acquired 14,286 shares of the stock in a transaction dated Thursday, October 23rd. The stock was acquired at an average price of $4.60 per share, with a total value of $65,715.60. Following the completion of the purchase, the insider owned 1,447,268 shares in the company, valued at $6,657,432.80. This trade represents a 1.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Arthur F. Golden bought 20,532 shares of the business’s stock in a transaction that occurred on Friday, November 21st. The shares were acquired at an average cost of $2.87 per share, for a total transaction of $58,926.84. Following the completion of the purchase, the director owned 50,734 shares in the company, valued at $145,606.58. This trade represents a 67.98% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have purchased 52,136 shares of company stock worth $183,463.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.